• Twitter
• Facebook
• Snapchat
• Pinterest
• LinkedIn
• Tumblr

---

Fundamental analysis: Arrowhead Pharmaceuticals, Inc. (ARWR)

Awarener score: 5.0

Conclusion

Note: All scores range from 1 (worst) to 10 (best). Conclusions are updated daily with closing stock prices and new reported quarterly financial statements.

Revenue score: 5.5

• Business has been growing at an excellent pace. It's been similar to peer companies.
• Arrowhead Pharmaceuticals, Inc. business varies frequently, ups and downs are normal. It's risky. It looks slightly worse than rivals.

Margins score: 3.7

• ARWR profit margins -on goods and services sold- are usually good. They stand slightly worse than rival companies.
• Business profit on sales tends to be very poor. It's great when measured against competitors.
• Profits on sales made -available to repay debt and purchase properties- are usually very poor. They remain excellent in relation to peers.
• Earnings -before income taxes and interests on loans taken- tend to be very poor in relation to total revenues. They're still better than most similar companies.
• Profits -before income taxes- are usually very poor considering total sales, and remain great when measured against rivals.
• Total net profit tends to be very poor when confronted to sales. Company stands great when measured against comparable firms.

Growth score: 2.1

• Arrowhead Pharmaceuticals, Inc. profit -on goods and services sold- has been growing at an excellent pace. It's been rather normal in relation to competitors.
• In recent years, the firm hasn't always been able to profit from operations, which has been bottom tier against comparable firms.
• In past years, the company couldn't always turn a profit -available to repay debt and purchase properties-, which compares last-in-rank when measured against peer enterprises.
• In the previous years, the firm couldn't always make a profit -before income taxes and interests on loans taken-. It turns to be a disappointment compared to similar stocks.
• In past years, at least once the company lost money -before income taxes-. It was bottom tier against rivals.
• In the previous years, the firm had at least a total net loss, and last-in-rank when measured against peer companies.
• The company lost money at least once in the past years. It's been a disappointment compared to industry peers.

Miscellaneous score: 3.0

• ARWR had still to pay income taxes, even though in recent past years mostly lost money. It's been bottom tier against peers.
• Research and development expenses consume a substantial portion of revenues. It's great when measured against competitors.
• The company grows sparsely in relation to research and development efforts. It stands in good shape compared to rival companies.

Profitability score: 3.8

• Arrowhead Pharmaceuticals, Inc. usually gets low returns on the resources it controls. It proves top tier when measured against peer firms.
• The company normally gets meagre proceeds -on the resources directly invested in the business-. They remain impressive in relation to similar companies.
• Profitability -in relation to owned resources- is usually lacking. It ranks great when measured against competitors.
• In the past, got low returns -on the tangible resources it controls-. This metric is usually related to the industry in which operates and combines profitability versus reinvestment needs. It's top tier when measured against comparable enterprises.

Usage of Funds score: 4.0

• ARWR on average doesn't generate genuine funds, so to buy or replace property, plants and equipment must either burn existing cash or increase debt. It stands top tier when measured against rival firms.
• The company is usually heavily investing in new property, plant, and equipment, to expand its operating capabilities, which is top tier when measured against industry peers.
• In the past twelve months the stock paid no dividends. It came bottom tier against competitors.
• The company pays no dividend, so measuring its growth is meaningless. The company has behaved in an conservative way compared to similar firms.
• As no dividends are paid, it is useless trying to estimate their sustainability in time. Sustainability looks not applicable in regard to comparable companies.
• The company somewhat enlarges a bit the pool of investors, resulting in more mouths feeding on the pie of profits. It remains impressive in relation to peer enterprises.
• Repurchase effectiveness metric is very complex. Run again in analytical mode if you're interested in a technical explanation. It stands in a very weak position compared to rivals.
• We do not have sufficient data to comment on buybacks and their sustainability. It still looks dubious against competitors.

Balance Sheet score: 6.3

• Arrowhead Pharmaceuticals, Inc. intangible assets (like brands and goodwill) represent a non-significant portion of resources controlled, according to accounting books, which is safer. It happens to be weak when measured against peer companies.
• The company has a lot more short-term resources than short-term obligations. There're no liquidity concerns. It turns to be rather normal in relation to similar firms.
• Roughly a tenth of resources controlled were provided for with financial debt. Creditors have minor claims on the company, and financial position is safe. It remains somewhat worse than rival firms.
• Resources controlled can be quickly made into cash, which is very good for liquidity and risk. It looks weak when measured against rivals.
• For every dollar of short-term obligations, the company has a lot of dollars in cash and short-term receivables. It's rather normal in relation to peer firms.
• For every dollar of short-term obligations, the company has a lot of dollars in cash and equivalents, which is slightly better than similar enterprises.
• Usually, sales are on somewhat more than three months credit. It still ranks weak when measured against peers.
• Days of inventory outstanding are not known. It comes up as a big question mark against competitors.
• We could not gauge the normal operating cycle of the company. It happens to be a mystery against peers.
• Unfortunately, we had not enough data to estimate the days of payables outstanding. It ranks unknown against industry peers.
• Cash conversion cycle remains unknown, due to not having enough inputs. It's incomparable against similar companies.
• Company earns net interest income on its investments and therefore is in a quite comfortable financial position. It stands top-notch against rival firms.
• Business has usually been operated at a loss. Unless prospects improve, the company is no position to decrease loans taken levels but by additional shareholders' funding. Profitability must improve. It ranks last-in-rank when measured against comparable enterprises.
• Revenues are low in relation to property, plant, and equipment required to operate. This metric is likely dependent on the industry the company operates in. The more property, plant, and equipment used, the more the company must reinvest to fight obsolescence, which usually means less available funds for the shareholders in the long run. It looks a slight improvement compared to similar firms.
• Resource exploitation is low when yearly sales are considered, business volume must be significantly increased. This metric is normally tied to the industry where the firm belongs. It's still better than most peer companies.

Valuation score: 3.4

• Arrowhead Pharmaceuticals, Inc. reported losses, so valuating it in relation to earnings is meaningless. It happens to be last-in-rank when measured against competitors.
• Price-to-Tangible-Book-Value is a fairly complex metric. Run again in analytical mode if you're interested in a technical explanation. It remains in a very weak position compared to peers.
• In the past twelve months, the company neither generated nor consumed funds. Whatever funds it could get, it reinvested in the business, which stands better than most similar companies.
• In the past years the company hardly generated enough genuine funds to cover up for its business needs. Business prospects should improve enough to be in a better position to reward investors. It's still top tier when measured against industry firms.
• In the past twelve months, the company has slightly enlarged the pool of investors by issuing new shares. The pie of earnings will now be split among a little more stockholders. It came up excellent in relation to peer ventures.
• The company has substantial more cash than debt. It might be poised to increase stockholder payments, or to fund new business projects. It looks mediocre against similar enterprises.
• Considering the past twelve months, traditional Price-to-Earnings relation has been negative, as the company lost money. It ranks last-in-rank when measured against peer companies.
• Comparing the current stock price with the past twelve-months revenues gives a huge relationship. The stock price might rely more on expectations and resources controlled than on anything else. It looks close to average when compared to rival firms.
• The relation between the stock price and accounting book value is extremely high, which may be good or bad depending on context. Run again in analytic mode if you want to dig deeper. The company remains worse than most peer firms.
• In the past twelve months, the operating business lost some money. It happens to be great when measured against industry peers.
• In an alternate metric of bang for the buck, the company has usually shown a somewhat low earnings power ability when measured against the current stock price and financial position. It's still impressive in relation to peer companies.

Total score: 4.0

---

Awarener score: 5.0

Conclusion

Support us!

We are an independent project. No ads, no suscription, no registration required.

• Donate!